Czech generic drug maker Zentiva denies report it is for sale (updated)

Zentiva SA

15/11/2021 07:47

(Adds Zentiva's rejection, details)
    PRAGUE, Nov 15 (Reuters) - Czech generic drug maker Zentiva
on Monday denied a report that its private equity owner Advent
International had plans to sell the company. 
    The Hospodarske Noviny daily newspaper earlier reported,
citing unnamed sources, that Advent planned to sell the company
in a transaction that could be worth 2.4 billion-3 billion euros
($2.8 billion-$3.4 billion). 
    One of the sources was quoted as saying the sale process
could start early next year. 
    "We are not for sale, for sure," Zentiva spokesperson
Mounira Lemoui said.
    Advent bought Zentiva for 1.9 billion euros including equity
and debt from France's Sanofi in 2018.
    Zentiva produces 564 formulations in its plants in the Czech
Republic, Romania and India, employing more than 2,300 people
combined.

    ($1 = 0.8726 euros)
    

 (Reporting by Robert Muller; Editing by Edmund Blair, Kirsten
Donovan)
 ((robert.muller@thomsonreuters.com; +420 234 721 615; Reuters
Messaging: robert.muller.thomsonreuters.com@reuters.net))